(3,5-二甲基-1H-吡唑-4-基)乙酸 | 32701-75-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: (3,5-二甲基-1H-吡唑-4-基)乙酸
• 英文名称: 2-(3,5-dimethyl-1H-pyrazol-4-yl)acetic acid
• 英文别名: (3,5-dimethyl-1H-pyrazol-4-yl)-acetic acid；(3,5-dimethyl-1H-pyrazol-4-yl)acetic acid
• CAS: 32701-75-0
• 化学式: C₇H₁₀N₂O₂
• mdl: MFCD05677521
• 分子量: 154.169
• InChiKey: HHILOQLQBYEUTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933199090

反应信息

• 作为反应物：
  描述：

  (3,5-二甲基-1H-吡唑-4-基)乙酸 在 1,2,2,6,6-五甲基哌啶 、 间甲苯磺酰氯 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成
  参考文献：
  名称：

  Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP)

  摘要：

  N-Myristoyltransferase (NMT) is an essential eukaryotic enzyme and an attractive drug target in parasitic infections such as malaria. We have previously reported that 2-(3-(piperidin-4-yloxy)benzo[b]thiophen-2-yl)-5-((1,3,5-trimethyl-1H-pyrazol-4-yl)methyl)-1,3,4-oxadiazole (34c) is a high affinity inhibitor of both Plasmodium falciparum and P. vivax NMT and displays activity in vivo against a rodent malaria model. Here we describe the discovery of 34c through optimization of a previously described series. Development, guided by targeting a ligand efficiency dependent lipophilicity (LELP) score of less than 10, yielded a 100-fold increase in enzyme affinity and a 100-fold drop in lipophilicity with the addition of only two heavy atoms. 34c was found to be equipotent on chloroquine-sensitive and -resistant cell lines and on both blood and liver stage forms of the parasite. These data further validate NMT as an exciting drug target in malaria and support 34c as an attractive tool for further optimization.

  DOI：

  10.1021/jm500066b
• 作为产物：
  描述：

  3-乙酰基-4-氧代戊酸乙酯 在 一水合肼 作用下， 以 甲醇 为溶剂， 反应 6.0h， 生成 (3,5-二甲基-1H-吡唑-4-基)乙酸
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS AND THEIR USE IN THERAPY
  [FR] NOUVEAUX COMPOSÉS ET LEUR UTILISATION EN THÉRAPIE

  摘要：

  这项发明提供了抑制N-肉豆蔻酰基转移酶并且对原生动物N-肉豆蔻酰基转移酶具有选择性的化合物，因此适用于治疗微生物感染，包括病毒和真菌感染，以及疟疾、利什曼病和睡眠病等原生动物感染。

  公开号：

  WO2013083991A1

文献信息

• [EN] NOVEL COMPOUNDS AND THEIR USE IN THERAPY<br/>[FR] NOUVEAUX COMPOSÉS ET LEUR UTILISATION EN THÉRAPIE
  申请人：IMP INNOVATIONS LTD

  公开号：WO2013083991A1

  公开（公告）日：2013-06-13

  The invention provides compounds which inhibit N-myristoyltransferase and are selective for protozoal N-myristoyltransferase and, consequently suitable to treat microbial infections, including viral and fungal infections, and protozoan infections such as malaria, leishmaniasis and sleeping sickness.

  这项发明提供了抑制N-肉豆蔻酰基转移酶并且对原生动物N-肉豆蔻酰基转移酶具有选择性的化合物，因此适用于治疗微生物感染，包括病毒和真菌感染，以及疟疾、利什曼病和睡眠病等原生动物感染。
• [EN] NEW PYRAZOLE DERIVATIVES HAVING CRTH2 ANTAGONISTIC BEHAVIOUR<br/>[FR] NOUVEAUX DÉRIVÉS DE PYRAZOLE POSSÉDANT UN COMPORTEMENT ANTAGONISTE DE CRTH2
  申请人：ALMIRALL SA

  公开号：WO2012069175A1

  公开（公告）日：2012-05-31

  The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

  本发明涉及一种式(I)的化合物，以及制备这种化合物的方法，以及它们在治疗病理状况或疾病中的应用，这些病理状况或疾病容易通过CRTh2拮抗活性得到改善。
• N-(Phenylmethyl)-2-(1H-Pyrazol-4-yl) Acetamide Derivatives as P2X7 Antagonists for the Treatment of Pain, Inflammation and Neurodegeneration
  申请人：Beswick Paul John

  公开号：US20090149524A1

  公开（公告）日：2009-06-11

  The present invention relates to novel pyrazole derivatives of formula (I) which bind to the P2X7 receptor and are capable of interfering with the effects of ATP at the P2X7 receptor: and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.

  本发明涉及一种新的嘧唑衍生物，其化学式为（I），该衍生物与P2X7受体结合，能够干扰ATP在P2X7受体上的作用：以及在治疗由P2X7受体介导的疾病，例如疼痛、炎症和神经退行性方面，使用此类化合物或其制剂的药物组合物。
• Dearomatization of oxa- or selenadiazolopyridines with neutral nucleophiles as an efficient approach to pharmacologically relevant nitrogen compounds
  作者：Alexey M. Starosotnikov、Dmitry V. Shkaev、Maxim A. Bastrakov、Ivan V. Fedyanin、Svyatoslav A. Shevelev、Igor L. Dalinger

  DOI：10.1016/j.mencom.2018.11.025

  日期：2018.11

  Highly electrophilic 6-nitro-4-azabenzofuroxan and 6-nitro-4-azabenzo[1,2,5]selenadiazole add pi-excessive (het)arenes and other neutral nucleophiles at 7-position to give C-C- and N-C-bonded adducts, 1,4-dihydropyridines fused with furoxan or selenadiazole ring.
• Miroslavov, A. E.; Sidorenko, G. V.; Lumpov, A. A., Journal of labelled compounds and radiopharmaceuticals, 2003, vol. 46, p. S250 - S250
  作者：Miroslavov, A. E.、Sidorenko, G. V.、Lumpov, A. A.、Gorshkov, N. I.、Suglobov, D. N.

  DOI：——

  日期：——